Allergy and Infectious Diseases Research (93.855)
Allergy and Infectious Diseases Research (Assistance Listing 93.855) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $22 billion in 13,282 grants from fiscal 2021 to 2025, about $1.6 million per award on average. 93 funding opportunities are open or forecast now.
The typical award was $599,596. Half of the 13,281 awards fell between $321,141 and $1.9 million, and they ranged from $0 to $446 million.
- Awarded, FY 2021 to 2025$22 billion
- Grant awards13,282
- Typical award$599,596
- Awarded in FY 2025$4.2 billion
- Size rank28 of 1,823
- Type of assistanceProject grants
Key findings
- Annual funding fell from $4.5 billion in fiscal 2021 to $4.2 billion in fiscal 2025.
- It is the 28th largest of 1,823 federal grant programs by five-year awards.
- The 20 largest recipients received 42% of the money.
- Awards went to recipients in 52 states and territories.
What the program funds
To assist public and private nonprofit institutions and individuals to establish, expand and improve biomedical research and research training in infectious diseases and related areas; to conduct developmental research, to produce and test research materials. To assist public, private and commercial institutions to conduct developmental research, to produce and test research materials, to provide research services as required by the agency for programs in infectious diseases, and controlling disease caused by infectious or parasitic agents, allergic and immunologic diseases and related areas. Projects range from studies of microbial physiology and antigenic structure to collaborative trials of experimental drugs and vaccines, mechanisms of resistance to antibiotics as well as research dealing with epidemiological observations in hospitalized patients or community populations and progress in allergic and immunologic diseases. Because of this dual focus, the program encompasses both basic research and clinical research. Small Business Innovation Research (SBIR) program expands and improves private sector participation in biomedical research. The SBIR Program intends to increase and facilitate private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. The Small Business Technology Transfer (STTR) program stimulates and fosters scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Research Career Development Awards support the development of scientists during the formative stages of their careers. Individual National Research Service Awards (NRSAs) are made directly to approve applicants for research training in specified biomedical shortage areas. In addition, Institutional National Research Service Awards are made to enable institutions to select and make awards to individuals to receive training under the aegis of their institutional program.
Open and forecast opportunities
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- Immune Tolerance Network (UM1 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed)
- Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
- Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)
- Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
- NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
- Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
- Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
Past notices
Of 403 notices posted under this program since 2021, most went up in March (49), August (42) and April (40).
- RFA-AI-27-004: Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)
- RFA-AI-27-012: Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)
- RFA-AI-27-016: Tuberculosis Research Advancement Centers (TRACs) (P30 Clinical Trial Not Allowed)
- RFA-AI-27-019: Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)
- RFA-AI-25-012: Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
- RFA-AI-25-013: Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed)
- RFA-AI-25-010: Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)
- RFA-AI-25-035: Influenza Transmission Research Consortium (P01 Clinical Trial Optional)
- RFA-AI-25-018: Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)
- RFA-AI-25-027: Tuberculosis Research Units (P01 Clinical Trial Optional)
- RFA-AI-25-022: Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)
- PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
- RFA-AI-24-079: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
- RFA-HL-26-009: Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed)
- RFA-HL-26-010: Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)
Rules from the program listing
Who can apply
Universities, colleges, hospitals, laboratories, and other public or private nonprofit domestic institutions, including State and local units of government, and individuals are eligible to make application for grant support of research by a named principal investigator or a research career development candidate. For-profit organizations are also eligible, with the exception of NRSA. Individual NRSA awardees must be nominated and sponsored by a public or nonprofit private institution having staff and facilities appropriate to the proposed research training program. All NRSA awardees must be citizens or have been admitted to the United States for permanent residence. To be eligible, predoctoral candidates must have completed the baccalaureate degree, and postdoctoral awardees must have a professional or scientific degree (M.D., Ph.D., D.D.S., D.O., D.V.M., Sc.D., D.Eng., or equivalent domestic or foreign degree). SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is being proposed and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions.
What the money can and cannot pay for
Beginning with fiscal year 1998, the direct costs awarded in the first year to a research project grant resulting from a competing renewal application will be limited to no more than a 20 percent increase over the direct costs awarded in the last non-competing year of that grant. Research grants provide funds for salaries, equipment, supplies, and travel. They also afford the collateral benefits of enriching the training experience of research workers. Grantees are expected to be judicious in using these funds. The application for a research grant sets forth specific terms and conditions and requires the signatures of the principal investigator and an official authorized to sign for the institution. Scientists and institutions are under an obligation to expend grant funds prudently for the purposes stated in the application and award document. For Research Career Development Awards (RCDAs) the scientists must demonstrate an outstanding research potential for independent research in the sciences related to transplantation, immunology, allergies, and immunological diseases. For National Research Service Awards (NRSAs), each individual who receives NRSA support is obligated upon termination of the award to comply with certain service and payback provisions. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Award range and average, in the agency's words
from $2,500 to $6,395,901 and the average $426,165.
Funding history and past recipients
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
Who usually wins
Colleges and universities received 67% of the money, nonprofits 24% and small businesses 4.8%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 9,404 | $15 billion | 67% |
| Nonprofits | 2,333 | $5.3 billion | 24% |
| Small businesses | 842 | $1.0 billion | 4.8% |
| Other | 683 | $825 million | 3.8% |
| Businesses | 5 | $30.4 million | 0.1% |
| State and local governments | 11 | $6.1 million | less than 0.1% |
| Tribal governments and organizations | 2 | $837,575 | 0% |
| Individuals | 2 | $354,078 | 0% |
By state
Each state below has its own page for this program, with its recipients and yearly totals.
| State | Awards | Amount |
|---|---|---|
| California | 1,598 | $3.4 billion |
| Massachusetts | 1,204 | $2.1 billion |
| Washington | 563 | $1.9 billion |
| New York | 1,154 | $1.8 billion |
| North Carolina | 583 | $1.5 billion |
| Maryland | 681 | $1.2 billion |
| Pennsylvania | 818 | $1.1 billion |
| Texas | 678 | $1.0 billion |
| Georgia | 468 | $817 million |
| Illinois | 449 | $567 million |
| Missouri | 371 | $565 million |
| Tennessee | 300 | $495 million |
| Ohio | 378 | $458 million |
| New Jersey | 202 | $396 million |
| Connecticut | 295 | $341 million |
| Colorado | 347 | $335 million |
| Minnesota | 227 | $323 million |
| Wisconsin | 224 | $286 million |
| Michigan | 237 | $277 million |
| Alabama | 160 | $271 million |
| Florida | 261 | $262 million |
| Virginia | 233 | $233 million |
| Oregon | 123 | $191 million |
| Indiana | 167 | $174 million |
| Iowa | 135 | $132 million |
| Utah | 99 | $132 million |
| Arizona | 103 | $131 million |
| District of Columbia | 80 | $116 million |
| Louisiana | 96 | $109 million |
| Oklahoma | 75 | $80.7 million |
| Kentucky | 83 | $76.6 million |
| New Hampshire | 59 | $71.6 million |
| Rhode Island | 135 | $66.5 million |
| South Carolina | 70 | $65.0 million |
| Nebraska | 58 | $60.1 million |
| Arkansas | 43 | $35.0 million |
| Vermont | 38 | $34.1 million |
| Maine | 10 | $34.0 million |
| New Mexico | 29 | $33.3 million |
| Kansas | 46 | $31.3 million |
| Montana | 27 | $19.2 million |
| West Virginia | 14 | $19.0 million |
| Nevada | 20 | $14.8 million |
| Hawaii | 12 | $10.0 million |
| Idaho | 14 | $9.2 million |
| Mississippi | 17 | $7.5 million |
| Delaware | 13 | $7.4 million |
| North Dakota | 9 | $4.2 million |
| Puerto Rico | 6 | $4.1 million |
| South Dakota | 4 | $3.2 million |
| Alaska | 1 | $2.7 million |
| Wyoming | 3 | $1.1 million |